RCT of risperidone versus haloperidol versus placebo with rescue haloperidol in delirium in palliative care

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/480476

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A simple definition of delirium is an acute confusional state that occurs when someone is unwell. It can manifest with many symptoms of varying severity, including confusion, restlessness, poor concentration and disturbance of sleep pattern. Delirium is a common problem when someone is unwell. Experience suggests that medications such as haloperidol and risperidone may be useful in managing these symptoms, however these have not been studied in detail in palliative care. This study is comparing the three approaches: use of risperidone given regularly, use of haloperidol given regularly, and use of haloperidol given as needed for symptoms of agitation, hallucinations and restlessness related to delirium in patients being cared for in palliative care settings. This study will compare how well these medications control delirium symptoms (from health professional, patient and caregiver perspectives) and also monitor their side effects over a five-day period, and follow longer term outcomes for 6 months (function and location of care).

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2011

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $50,000.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Antipsychotic | Cancer | Cognitive Impairment | Palliative Care

Related Links